{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:57:52Z","timestamp":1785473872046,"version":"3.56.0"},"reference-count":68,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic disease that requires long\u2010term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)\u201023. This article reviews published data on the safety of these <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201023p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo\u2010 and active\u2010controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk\u2013benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201023p19 inhibitors in the data published to date. The most commonly reported adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous <jats:italic>Candida<\/jats:italic> infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201023p19 may help avoid <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s that have been associated with biologic agents with other mechanisms of action. Data from long\u2010term extension studies and patient registries will further establish the safety profile of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201023p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice.<\/jats:p>","DOI":"10.1111\/jdv.15653","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T14:08:55Z","timestamp":1557151735000},"page":"1676-1684","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Safety of selective <scp>IL<\/scp>\u201023p19 inhibitors for the treatment of psoriasis"],"prefix":"10.1111","volume":"33","author":[{"given":"J.J.","family":"Crowley","sequence":"first","affiliation":[{"name":"Bakersfield Dermatology Bakersfield CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre Salford Royal NHS Foundation Trust Hospital Manchester NIHR Biomedical Research Centre University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Cather","sequence":"additional","affiliation":[{"name":"Mindful Dermatology and Modern Research Associates Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Global Report on Psoriasis","author":"World Health Organization","year":"2016"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2014.02.012"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14433"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297"},{"key":"e_1_2_6_6_1","unstructured":"Amgen.ENBREL\u00ae(etanercept). Highlights of prescribing information. November2017. URLhttps:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/enbrel\/enbrel_pi.pdf(last accessed: 10 October 2018)."},{"key":"e_1_2_6_7_1","unstructured":"AbbVie.HUMIRA\u00ae(adalimumab). Highlights of prescribing information. August2018. URLhttps:\/\/www.rxabbvie.com\/pdf\/humira.pdf(last accessed: 10 October 2018)."},{"key":"e_1_2_6_8_1","unstructured":"Janssen Biotech.REMICADE\u00ae(infliximab). Highlights of prescribing information. June2018. URLhttp:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/REMICADE-pi.pdf(last accessed: 10 October 2018)."},{"key":"e_1_2_6_9_1","unstructured":"UCB I.CIMZIA\u00ae(certolizumab pegol). Highlights of prescribing information. June2018. URLhttps:\/\/www.cimzia.com\/sites\/default\/files\/docs\/CIMZIA_full_prescribing_information.pdf(last accessed 10 October 2018)."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.013"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0121-x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081463"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200439"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1736"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"},{"key":"e_1_2_6_22_1","unstructured":"Valeant Pharmaceuticals.SILIQ\u2122(brodalumab). Highlights of prescribing information. February2017. URLhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf(last accessed: 10 October 2018)."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.011"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.041"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"e_1_2_6_26_1","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp K","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_27_1","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette R","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.304"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04705.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1145"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2014.33"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.22.13125"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2110-5"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16236"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14175"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15012"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16724"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0198-x"},{"key":"e_1_2_6_51_1","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"12","author":"Sbidian E","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1422591"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.020"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209831"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30233-4"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5937"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382"},{"key":"e_1_2_6_60_1","unstructured":"HaycraftK KimballAB BrunnerMet\u00a0al.Outcomes of pregnancies from tildrakizumab phase 1\u20133 clinical development programPaper presented at: Dermatology Education Foundation Essential Resource Meeting 2018 NP\/PA CME Conference 2018; Las Vegas NV USA."},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1468066"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17086"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.08.041"},{"key":"e_1_2_6_64_1","first-page":"1122","article-title":"Immune response to pneumococcus and tetanus toxoid in patients with moderate\u2010to\u2010severe psoriasis following long\u2010term ustekinumab use","volume":"12","author":"Brodmerkel C","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_65_1","unstructured":"Janssen Biotech.STELARA\u00ae(ustekinumab). Highlights of prescribing information. October2017. URLhttp:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf(last accessed: 25 October 2018)."},{"key":"e_1_2_6_66_1","unstructured":"Janssen Biotech.TREMFYA\u00ae(guselkumab). Highlights of prescribing information. October2017. URLhttp:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf(last accessed: 25 October 2018)."},{"key":"e_1_2_6_67_1","unstructured":"Sun Pharmaceutical Industries.ILUMYA\u2122 (tildrakizumab\u2010asmn). Highlights of prescribing information. August2018. URLhttps:\/\/www.ilumyapro.com\/assets\/pdf\/Sun_Pharma_ILUMYA_US_Prescribing_Information.pdf(last accessed: 25 October 2018)."},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2018.048"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.002"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.15653","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:58:20Z","timestamp":1694066300000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/jdv.15653"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15653","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"2019-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}